Which DME patients are likely to achieve extended Tx intervals with faricimab?
05 Mar 2026
byNatalia Reoutova
Treatment naivety, lower baseline intraretinal fluid (IRF) and subretinal fluid (SRF) volume, lower baseline central subfield thickness (CST), greater IRF and SRF volume reduction, and greater CST reduction at week 16 in patients with diabetic macular oedema (DME) are predictive of longer treatment intervals with faricimab 6.0 mg at years 1 and 2, according to the results of the phase III YOSEMITE/RHINE trials.
